{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:58:43Z","timestamp":1790881123834,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dazhou City Key Research and Development Project of Science and Technology","award":["24ZDYF0001"],"award-info":[{"award-number":["24ZDYF0001"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This retrospective cohort study evaluated the clinical value and short-term prognostic outcomes of cytoreductive radical prostatectomy using the cytoreductive radical prostatectomy (CRP) technique combined with pharmacotherapy in patients with oligometastatic prostate cancer (OPC). Consecutive OPC patients treated between January 2023 and December 2023 were included. According to the actual treatment received, patients were assigned to a pharmacotherapy group (control) or a CRP technique plus pharmacotherapy group (study), with 47 patients in each group. All patients were followed for 24 months. Baseline demographics and clinical variables were compared between groups. Treatment response was assessed using Prostate Cancer Working Group 3 criteria. Serum prostate-specific antigen levels were recorded at baseline and at 2, 6, and 12 months. Quality of life, pain, and anxiety were evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, visual analog scale, and generalized anxiety disorder-7, respectively. Complications were graded by the Clavien\u2013Dindo classification. Survival outcomes were analyzed using Kaplan\u2013Meier methods. Baseline characteristics were comparable between groups. The CRP combined with intensified systemic therapy showed a higher proportion of complete\/partial response and a lower proportion of progression than the pharmacotherapy group. Between-group differences in prostate-specific antigen were evident at the 2-month assessment. Posttreatment European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores were higher, whereas visual analog scale and generalized anxiety disorder-7 scores were lower, in the combined-treatment group. Complications were infrequent and limited to grade I events, with no between-group difference. No deaths occurred during follow-up; progression-free survival was longer in the combined-treatment group. Cytoreductive radical prostatectomy using the CRP technique combined with pharmacotherapy was associated with improved short-term disease control and progression-free survival without an apparent increase in complications in OPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049826","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:01:56Z","timestamp":1784919716000},"page":"e49826","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-term clinical outcomes of cytoreductive radical prostatectomy combined with abiraterone-based androgen deprivation therapy in oligometastatic prostate cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Bai","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7575-1899","authenticated-orcid":false,"given":"Chao","family":"Huang","sequence":"additional","affiliation":[{"name":"Dazhou Central Hospital, Dazhou, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.euo.2022.08.004","article-title":"Radical prostatectomy or radiotherapy in oligometastatic prostate cancer: is it nearly time to call it a draw?","volume":"5","author":"Graefen","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R2-20261001","first-page":"55","article-title":"The cytoreductive radical prostatectomy in metastatic prostate cancer.","volume":"35","author":"Vladimir","year":"2022","journal-title":"Klin Onkol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOU.0000000000001180","article-title":"Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging.","volume":"34","author":"Robesti","year":"2024","journal-title":"Curr Opin Urol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.urology.2023.09.014","article-title":"Does radical local treatment in oligometastatic prostate cancer improve overall survival: a systematic review and meta-analysis.","volume":"182","author":"Madhavan","year":"2023","journal-title":"Urology"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41391-024-00838-8","article-title":"Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence.","volume":"28","author":"Dorff","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2021.06.015","article-title":"Primary tumor treatment in oligometastatic prostate cancer: radiotherapy versus radical prostatectomy.","volume":"35","author":"Knipper","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"111774","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur J Radiol"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.04.016","article-title":"The EORTC CAT core \u2013 the computer adaptive version of the EORTC QLQ-C30 questionnaire.","volume":"100","author":"Petersen","year":"2018","journal-title":"Eur J Cancer"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00004630-199509000-00013","article-title":"The Vancouver Scar Scale: an administration tool and its interrater reliability.","volume":"16","author":"Baryza","year":"1995","journal-title":"J Burn Care Rehabil"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.juro.2010.05.032","article-title":"Reporting complications after open radical retropubic prostatectomy using the Martin criteria.","volume":"184","author":"Loppenberg","year":"2010","journal-title":"J Urol"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"100597","DOI":"10.1016\/j.esmoop.2022.100597","article-title":"The current role of precision surgery in oligometastatic prostate cancer.","volume":"7","author":"von Deimling","year":"2022","journal-title":"ESMO Open"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11934-023-01173-6","article-title":"Local therapeutics for the treatment of oligo metastatic prostate cancer.","volume":"24","author":"Jalfon","year":"2023","journal-title":"Curr Urol Rep"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"812549","DOI":"10.3389\/fonc.2021.812549","article-title":"Clinical significance of mesenchymal circulating tumor cells in patients with oligometastatic hormone-sensitive prostate cancer who underwent cytoreductive radical prostatectomy.","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/cancers17172757","article-title":"Role of radical prostatectomy in oligo-metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.","volume":"17","author":"Rajan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"15330338231216011","DOI":"10.1177\/15330338231216011","article-title":"Current controversy and developments regarding the cytoreductive prostatectomy for oligometastatic prostate cancer.","volume":"22","author":"Tian","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.euf.2023.01.011","article-title":"Cytoreductive radical prostatectomy for metastatic hormone-sensitive prostate cancer-evidence from recent prospective reports.","volume":"9","author":"Rajwa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euf.2019.05.008","article-title":"Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer-translational research results from the prospective ProMPT trial.","volume":"7","author":"Mandel","year":"2021","journal-title":"Eur Urol Focus"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European study.","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:00:57Z","timestamp":1790877657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":19,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049826","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2026-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}